Alkylating agents are widely used chemotherapeutics in the treatment of many cancers, including leukemia, lymphoma, multiple myeloma, sarcoma, lung, breast and ovarian cancer. Melphalan is the most commonly used chemotherapeutic agent against multiple myeloma. However, despite a 70-80% initial response rate, virtually all patients eventually relapse due to the emergence of drug-resistant tumour cells. By using global proteomic and transcriptomic profiling on melphalan sensitive and resistant RPMI8226 cell lines followed by functional assays, we discovered changes in cellular processes and pathways not previously associated with melphalan resistance in multiple myeloma cells, including a metabolic switch conforming to the Warburg effect (aerobic glycolysis), and an elevated oxidative stress response mediated by VEGF/IL8-signaling. In addition, up-regulated aldo-keto reductase levels of the AKR1C family involved in prostaglandin synthesis contribute to the resistant phenotype. Finally, selected metabolic and oxidative stress response enzymes were targeted by inhibitors, several of which displayed a selective cytotoxicity against the melphalan-resistant cells and should be further explored to elucidate their potential to overcome melphalan resistance.
Introduction
Multiple myeloma (MM) is an incurable bone marrow disease and the second most common hematological cancer. The median age of onset is 65 years and progression often leads to severe complications including immunodeficiency, osteolytic bone disease and renal failure [1] .
Although current therapies may improve the patient's survival, disease progression and acquired drug resistance remain unsolved issues. Since the 1960s, the alkylating drug melphalan (L-phenylalanine mustard) has been employed in combination with corticosteroids as first-line therapy for MM [2] . Novel agents such as bortezomib and lenalidomide have recently been introduced, but melphalan remains the standard therapy for transplant-ineligible patients and is the basis for high-dose therapy associated with autologous stem cell transplant [3] . Melphalan's efficacy has been attributed to its ability to induce cytotoxic interstrand cross-links (ICLs) in DNA [4] , but it may also induce other lesions in DNA [5] , RNA, proteins and lipids [6] . The mechanisms by which melphalan kills tumor cells thus remain elusive and identifying factors that attenuate melphalan sensitivity is crucial to improving therapeutic outcomes.
Acquired melphalan resistance in MM has been associated with reduced drug uptake [7] , increased drug detoxification [8, 9] , reduced ICL formation and enhanced DNA repair of ICL lesions [10] [11] [12] , modulation of DNA base excision and strand break repair [13, 14] , adaptation to reactive oxygen species (ROS) [15] and decreased apoptosis [16] ; however, there are no robust biomarkers that predict melphalan resistance.
Here we have used transcriptomics and proteomics to investigate cellular changes associated with acquired melphalan resistance in the RPMI8226 multiple myeloma cell line. We observed a metabolic switch conforming to the Warburg effect in the melphalan-resistant cell line accompanied by an increased oxidative stress response and enhanced survival and proliferation signaling. The increased survival was partially mediated through VEGF-and IL8-induced PI3K/p38 signaling and upregulated expression of the AKR1C family of aldo-keto reductases. We demonstrate that targeting enzymes within the affected pathways by specific inhibitors can overcome acquired melphalan resistance.
Materials and Methods

Reagents and antibodies
For Western analysis antibodies to AKR1C2 (H00001646-D01, Abnova), AKR1C3 (H00008644-B01, Abnova), AKR1C4 (H00001109-M01, Novus), AKT1 (#2967, Cell Signaling), Caspase3 (sc-7148, Santa Cruz), SLC16A3 (OAAB08662, Aviva Systems Biology) PARP-1 (sc-74470, Santa Cruz), STAT3 (sc-81385, Santa Cruz), pSTAT3 (S2690, Sigma) and β-actin (ab8226, Abcam) primary antibodies and HRP-conjugated secondary antibodies (Dako) were used. Melphalan, ursodeoxyholate, indomethacin, flufenamic acid, dichloroacetic acid, 2-deoxy-D-glucose, sodium oxamate, metformin, oligomycin, antimycinA, FLLL31, wortmannin, rapamycin, methyl glyoxal, acetylsalicylic acid, ibuprofen, (Sigma Aldrich), tert-butyl peroxide (Fluka), LY294002, SB203580 and BIRB0796 (Cell Signaling) were used in viability assays.
Cell lines and preparation of cell extracts
MM cell lines RPMI8226 and RPMI8226-LR5 were kindly donated by Prof. William S. Dalton at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA. Cells were maintained, treated with melphalan and cell extracts prepared as previously described [13] .
mRNA isolation and analysis mRNA was isolated from six batches each of control and melphalan-treated RPMI8226 and RPMI8226-LR5 cells using the mirVana mRNA isolation kit (Ambion). RNA concentration and quality were determined using NanoDrop ND-8000 (NanoDrop Technologies) and Agilent 2100 Bioanalyzer (Agilent). RIN values of RNA samples used for cRNA amplification ranged from 8.5 to 10 (mean = 9.49). The Illumina TotalPrep RNA amplification Kit (Ambion) was used to amplify mRNA for hybridization on Illumina BeadChips. First strand cDNA was synthesized from each mRNA sample. Following second strand synthesis and purification, cRNA was synthesized for 12 hours. Gene expression profiles were measured using Illumina HumanHT-12_V3 Expression BeadChip. Raw data were exported from Illumina GenomeStudio to R using the Bioconductor package`lumi`version 2.1.3. [17] . Data were quantile normalized and log 2 transformed. The groups were compared using a t-test with empirical Bayes correction from the Bioconductor package`Limma` [18] . The fold change was used to demonstrate rate of changes in average gene expressions between studied groups. Statistical analyses were performed using the false discovery rate (FDR) with a significance threshold of 0.01. The transcriptomic data have been deposited to the GEO repository with the identifier GSE60970 [19] .
Western analysis, viability assay and mROS analysis
Western analysis and MTT assays were performed as described [13] . mROS was analyzed using MitoSOX Red (Molecular Probes) according to the manufacturer's protocol. Briefly, cells (0.5 × 10 6 cells/ml) were pretreated with inhibitors for 6 h, washed with HBBS and incubated with MitoSOX for 10 min at 37°C. Flow cytometry was performed at 510 nm excitation and 580 nm emissions.
Cytokine and lactate analysis
Briefly cells (0.5 × 10 6 cells/ml) were incubated in RPMI1640 medium until they reached approximately 1 × 10 6 cells/ml and 80% viability. Medium (50 μl) was used for cytokine measurements in duplicates using the Bioplex 27-plex human cytokine kit from BioRad as per manufacturer's instructions. Bioplex manager software was used for calculation of cytokine concentrations. Standard curves were optimized by the software and verified manually. Lactate levels were measured using the L-Lactate Assay Kit according to the manufacturer's protocol (Cayman medium, respectively (Pierce SILAC protein Quantitation kit-RPMI1640). Sensitive and resistant cells were mixed 1:1 and cell extracts prepared as above. Proteins were separated on 4-12% denaturing NuPAGE (Invitrogen) and stained with Simply Blue TM (Invitrogen). Thirteen bands were excised, reduced and alkylated prior to trypsin in-gel digestion as described [20] . Peptides were eluted with 50% acetonitrile in 5% formic acid and lyophilized before MS analysis. LC-MS/MS was conducted on an EASY-nLC (Proxeon) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo). Reconstituted samples were separated on an in-house 15 cm fused silica column (100 μm i.d., 375 μm o.d.) using a 50 min gradient up to 32% ACN in 0.1% formic acid and 250 nl/min flow rate. MS scans (300-1800 m/z) were acquired at a resolution of 60,000 (m/z 400) in the Orbitrap. During each duty cycle, up to five of the most intense peptides were selected for CID fragmentation in the ion trap. Raw files were processed in MaxQuant v. 
Results
Illumina and SILAC gene expression profiling
To investigate large scale alterations in gene expression accompanying melphalan resistance, we used the multiple myeloma cell line RPMI8226 and its melphalan-resistant derivative LR5. The stable isotope labeling by amino acids in cell culture (SILAC) approach resulted in the identification of 1042 proteins, of which 668 were quantified using MaxQuant (PEP <0.01) (S1 Table) . The histogram of the log 2 SILAC ratios showed a normal distribution centered at zero, supporting similar overall protein loads of the H/L samples (Fig. 1A) . Illumina HumanHT-12_V3 annotation data were used for mapping mRNA expression and led to 4580 identifications with p-values < 0.05 (S2 Table) . We considered differentially expressed genes (DEGs) exhibiting an absolute fold change above 1.25 because the cell lines were isogenic and proliferated similarly. This resulted in 424 and 2842 unique proteins and mRNAs, respectively (S1and S2 Tables), of which 175 proteins and mRNAs overlapped (Fig. 1B) . We observed a high correlation of expression data from the protein and mRNA analyses (up-regulated R 2 = 0.91, downregulated R 2 = 0.72, Fig. 1C ). The most differentially regulated proteins in the SILAC analyses are listed in Table 1 together with their corresponding fold changes at the mRNA level.
Melphalan-resistant RPMI8226 cells display altered expression of metabolic enzymes conforming to the Warburg effect ), and several other respiratory metabolism pathways were also significantly altered (Fig. 1D, E) . Specifically, most of the glycolytic and pentose phosphate pathway (PPP) enzymes were up-regulated in the resistant cells, whereas the tri-carboxylic acid (TCA) cycle and electron transport chain proteins were down-regulated (Fig. 2) . Such a metabolic switch is a characteristic feature of the Warburg effect [23] , which is considered a survival mechanism in cancerous tissues [24] that also mediates resistance to apoptosis [25] and to oxidative stress [26] . The underlying mechanisms leading to the Warburg effect are not well understood. However, a number of oncogenes, including c-MYC, are known to enhance the expression of glycolytic enzymes, such as lactate dehydrogenase (LDHA) [27] . Although c-MYC was not quantified by SILAC, its mRNA was 1.8-fold up-regulated in the melphalan-resistant cells (S2 Table) and 1.5-fold upregulated as quantified by western blot (data not shown). 
Melphalan-resistant cells display markedly increased sensitivity towards inhibitors targeting turnover of glycolytic intermediates
To further analyze the significance of carbohydrate metabolism in melphalan resistance, sensitive and resistant cells were grown in the presence or absence of glucose. Glucose deprivation had a significantly stronger growth-inhibitory effect in resistant cells compared to sensitive cells (Fig. 3A) . We then subjected both cell lines to treatment with enzyme inhibitors that target different steps in glycolysis and the PPP. 2-deoxy-D-glucose (2-DG) inhibits hexokinase (HK) and phosphoglucoisomerase (GPI) and thus funneling of precursors into both glycolysis and PPP. Blocking glycolysis causes ATP depletion, cell cycle arrest and cell death, while blocking PPP inhibits NADPH synthesis and reduces the antioxidant capacity of the cells. 6-aminonicotinamide (6-AN) potently inhibits glucose-6-phosphate dehydrogenase (G6PD) and selectively inhibits PPP. G6PD was more than two-fold up-regulated in the melphalan-resistant cells according to the SILAC analyses. Sodium oxamate (SO) inhibits the conversion of pyruvate to lactate by LDHA, thus inhibiting glycolysis by depleting NAD + [28] . Finally, dichloroacetate (DCA) inhibits all pyruvate dehydrogenase kinase (PDK) isoenzymes, thus increasing the activity of pyruvate dehydrogenase (PDH) and increasing the acetyl-CoA introduced into the TCA cycle [29] . All of these inhibitors had a significantly stronger growth-inhibitory effect upon melphalan-resistant cells and this was also observed when inhibitors were combined with 2.5 μM melphalan (Fig. 3A) . This corroborates that a metabolic switch towards aerobic glycolysis contributes to the melphalan-resistant phenotype.
Melphalan-resistant cells display increased tolerance to overall oxidative stress, but are sensitive to mitochondrial electron transport inhibitors DCA mediated the largest selective effect against the resistant cells (Fig. 3A) . This inhibitor does not directly target glycolytic or PPP enzymes. We thus measured mitochondrial ROS subsequent to DCA-treatment to examine whether increased metabolic flux into mitochondria was less tolerated by the melphalan-resistant cells. As illustrated in Fig. 3B increased mitochondrial ROS was selectively induced in the melphalan-resistant cells subsequent to DCA-treatment. Western analysis of PARP1 and caspase-3 revealed weak induction of PARP1 cleavage in both cell lines subsequent to DCA treatment, whereas combined DCA/melphalan treatment mediated markedly increased cleavage of both PARP1 and caspase-3 in the melphalan-resistant cells (Fig. 3C ). Increased mitochondrial stress may reduce the mitochondrial capability to regenerate NAD + to support glycolytic ATP-production. This would more severely impact the resistant cells given their increased dependence upon glycolytic ATP-production. We tested this by treating the cells with electron transport chain inhibitors (metformin and antimycin A) or with the ATP synthase inhibitor oligomycin. Metformin and antimycin A were more toxic to the resistant cells both in the presence and absence of 2.5 μM melphalan, whereas oligomycin was more toxic to the sensitive cells under both conditions (Fig. 3D) further confirm the increased dependence of the melphalan-resistant cells to glycolytic ATP production. The melphalan-resistant cells were also more tolerant towards the unspecific pro-oxidant tert-butyl hydroperoxide (t-BHP) (Fig. 3D) . The cytotoxic effects of t-BHP have been shown to be counteracted by activation of the NRF2-mediated stress response [30] . In affirmation of this, we observed that NRF2 mRNA was significantly up-regulated (1.5 ×) in the resistant cells and the NRF2-mediated oxidative stress response was reported to be significantly (p = 1.03 × 10 -4 ) modulated in the IPA analysis. From these results we concluded that the melphalan-resistant cells are more tolerant of oxidative stress, mediated at least partially by NRF2, but are selectively sensitive towards drugs that inhibit NAD + regeneration.
Lactate accumulation and IL8/VEGF signaling contribute to increased survival in the melphalan-resistant cells
The observed metabolic shift should result in increased lactate production in the resistant cells to regenerate NAD + and facilitate glycolytic ATP production. We found a higher intracellular but lower extracellular lactate content in the melphalan-resistant cells (Fig. 4A) , indicating that lactate is retained in the melphalan-resistant cells. Lactate is exported from cells by the monocarboxylate transporters of the SLC16 family, of which SLC16A3 (MCT4) is the major lactate transporter in leukocytes [31] . SLC16A3 was 4.7-fold down-regulated at the mRNA level in the melphalan-resistant cells (S2 Table) , but was not quantified in the SILAC analysis. Western analysis of SLC16A3 revealed no significant reduction in the melphalan-resistant cells (Fig. 4B) . Lactate can serve as metabolic fuel in certain cell types via the proposed cytoplasmic/mitochondrial lactate shuttle [32, 33] . In addition, lactate may act as a signaling molecule inducing a pseudo-hypoxic condition leading to up-regulation of NF-κB/IL-8 and pro-angiogenic VEGF [34] . The latter is also supported by the co-regulated expression of lactate dehydrogenase and VEGF in tumor cells [35] . We found that IL-8 was 4.4-fold up-regulated at the mRNA level (S2 Table) and both IL-8 and VEGF secretion were increased (>12-and 1.7-fold, respectively) in the melphalan-resistant cells (Fig. 4C) . IL-8 and VEGF can mediate pro-survival and proliferation responses through alternative downstream pathways. One of the downstream effectors of IL-8 is STAT3 [36] , which has emerged as a potential oncogene target in many solid and hematologic cancers, including MM [37] . However, we found no difference in STAT3 mRNA levels in the sensitive and resistant cells (S2 Table) . Moreover, western analysis revealed no induction of total-or phosphorylated (pY705) STAT3 protein in the resistant cells (Fig. 4D) . We also subjected the cells to treatment with the STAT3 inhibitor FLLL31, and found that the inhibitor selectively reduced viability in the melphalan-sensitive cells both in the absence and presence of 2.5 μM melphalan (Fig. 4E ). An explanation to this could be that alternative survival pathways are up-regulated in the melphalan-resistant cells making them less dependent on STAT3 signaling. To further investigate the impact of IL-8/VEGF signaling, we subjected the cells to inhibitors that target downstream effectors of IL-8 and VEGF, specifically within the PI3K and p38 MAPK signaling pathways. LY294002 and wortmannin are kinase inhibitors that target PI3K, and rapamycin inhibits mTOR downstream of PI3K. All the PI3K/mTOR inhibitors were more cytotoxic to the melphalan-resistant cells and abolished the selective proliferation advantage of the resistant cells observed with 2.5 μM melphalan alone (Fig. 4E) . The mTOR pathway has been suggested to be a potential therapeutic target in myeloma characterized by up-regulated AKT1 [38] . We did not observe a difference in mTOR and AKT1 mRNA levels between melphalan-resistant and sensitive cells (S2 Table) and could not quantify the proteins by SILAC. We therefore measured AKT1 by western blot and found that AKT1 and pAKT1 expression is decreased in melphalan-resistant cells (Fig. 4F) . Thus, mTOR inhibition does not fully explain the selective cytotoxicity of these inhibitors in melphalan-resistant cells.
The p38 MAPK inhibitor SB203580 is strictly selective for p38α and β, whereas BIRB0796 inhibits p38α, β, δ and γ [39] . In addition, SB203580 inhibits CK1, GSK3, RIP2 and GAK, and BIRB0796 inhibits JNK2 [38] . BIRB796 was much more cytotoxic in the melphalan-resistant cells, having little effect on the resistant cells, whereas SB203580 showed no selectivity towards either cell line when administered alone. However, both inhibitors reversed the selective growth advantage of the melphalan-resistant cells in 2.5 μM melphalan (Fig. 4B ). Taken together, the selective cytotoxicity of inhibitors acting downstream of IL-8/VEGF supports a role of IL-8/VEGF-signaling in acquired melphalan resistance in MM.
A potential role of aldo-keto reductases in melphalan resistance
The aldo-keto reductase AKR1C enzymes constitute a family of oxidoreductases that catalyze NADPH-dependent reduction of a wide variety of substrates [40] . Here, AKR1C1-3 regulate ligand occupancy and trans-activation of androgen-, estrogen-and progesterone receptors, the peroxisome proliferator-activated receptor (PPARγ) as well as the prostaglandin metabolism [41] . AKRC1 members displayed the most pronounced up-regulated expression in both the SILAC and mRNA profiling analyses (Fig. 5A ). Due to their extensive sequence homology (84% to 98%), AKR1C1-4 were collectively reported as 12-fold up-regulated in SILAC. AKR1C2, 3 and 4 mRNA were 37-, 25-and 22-fold up-regulated, respectively. We also measured AKR1C2, C3 and C4 by western blot and observed the most prominent up-regulation of AKR1C2 and C3 (15.6-and 28.2-fold, respectively, Fig. 5A, B) . Moreover, enzyme levels did not increase in either cell line after 50 μM melphalan treatment (Fig. 5B) , indicating that their up-regulation is a result of adaptation to prolonged treatment with low dose melphalan rather than an immediate stress response mediated by short time exposure to high dose melphalan.
To explore the potential role of AKR1C2 and C3 in the melphalan resistance mechanism, melphalan-sensitive and-resistant cells were treated with aldo-keto reductase inhibitors. Flufenamic acid (FA) is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory and antipyretic properties and acts as a broad-spectrum AKR1C inhibitor. In addition it modulates several channel activities and is an activator of AMP-activated protein kinase [42] . Indomethacin (IM) is an NSAID commonly used to reduce fever and pain by inhibiting the production of prostaglandins, and inhibits AKR1C3 much more potently than AKRC1 and AKRC2 [43, 44] . IM and FA are also nanomolar and micromolar inhibitors, respectively, of COX-1/2 (PTGS1/2) [45] . Previous work suggests, however, that the antiproliferative effect of IM upon myeloma cells is independent of COX-2 [46] . Notably FA and IM were moderately selectively cytotoxic to the melphalan-resistant cells when administered alone (Fig. 5C, left  panel) . When administered together with melphalan, both inhibitors markedly reversed the resistant phenotype (Fig. 5C, right panel) . To further investigate the specific role of AKR1C in the melphalan-resistant cells we also tested the non-NSAID drug ursodeoxycholate (UDC). UDC is a bile acid drug that reduces cholesterol absorption and is used to treat primary biliary cirrhosis. It inhibits both AKR1C2 and C3 and has been shown to have pro-and anti-apoptotic properties depending on the cell lines and experimental systems employed [47, 48] . Importantly, UDC mediated a nearly complete reversal of the melphalan-resistant phenotype, similar to that seen with FA (Fig. 5C, right panel) . These results strongly suggest that AKR1C2 and C3 contribute to melphalan resistance in the myeloma cells. However, to further investigate whether a general effect mediated by NSAID treatment was involved in reversal of resistance, the cells were also treated with acetylsalicylic acid or ibuprofen. As demonstrated in Fig. 5D , such treatment did not mediate any change in the relative resistance of the myeloma cells, further substantiating that FA and IM primarily affect melphalan resistance by AKR1C inhibition.
In a recent study of aldehyde toxicity in neuroblastoma cells, Lyon et al. [49] demonstrated that the AKR1C3 protein level could be induced by short-time treatment with sub-lethal doses of either methyl glyoxal or 4-hydroxy-2-nonenal (4HNE). These reactive aldehydes are increased in several neurodegenerative diseases [50] and recombinant AKR1C1-3 have been shown to possess high specific activities against 4HNE [51] . Incubation of the melphalan-sensitive and-resistant cells in 1 μM methyl glyoxal for 24 h mediated a strong up-regulation of AKR1C3 in the melphalan-sensitive cells whereas the AKR1C3 level remained unaltered in the resistant cells. AKR1C2 was also up-regulated by the pretreatment, but much weaker than AKR1C3 (Fig. 5E) . The treatment did not mediate any cytotoxic effect in the cells (Fig. 5F ). However, subsequent treatment of the cells in 2.5 μM melphalan demonstrated that the methyl glyoxal pretreatment mediated a resistant phenotype in the parental RPMI8226 cells resembling that of the LR5 derivative (Fig. 5F ). These results corroborate the inhibitor studies and support a role of AKR1C aldo-keto reductases in mediating melphalan resistance in the myeloma cells.
Discussion
MM is a complex and heterogeneous disease and as such, many factors likely contribute to acquired melphalan resistance. Here we used a transcriptomic and proteomic approach to identify key proteins involved in melphalan resistance in isogenic myeloma cell lines. We thereby demonstrated an active involvement of a metabolic switch in melphalan-resistant cells towards aerobic glycolysis accompanied by an increased tolerance towards oxidative stress. Aerobic glycolysis (Warburg effect) has been largely ignored in cytostatic resistance research, but several recent findings indicate that combining cytostatics with targeted inhibition of aberrant cellular metabolism may overcome chemorefractoriness [52] . We similarly targeted the glycolytic pathway with 2-DG, 6-AN and SO and found that they were selectively cytotoxic to melphalan-resistant cells. 2-DG has recently been implemented in phase-I clinical trials in patients with advanced solid tumors [53] and its cytotoxicity has been partially attributed to glycolytic inhibition.
DCA was also selectively cytotoxic to the melphalan-resistant cells, and this is corroborated by Sanchez et al., who demonstrated a selective effect of DCA in multiple myeloma cell lines having high aerobic glycolysis [54] . DCA also increased the sensitivity of these cells towards the proteasome inhibitor bortezomib. ROS induction has been demonstrated to play a critical role in bortezomib-induced apoptosis by disrupting the mitochondrial membrane potential [55] , and DCA has been shown to synergistically inhibit proliferation in melanoma cells with induced mitochondrial ROS [56] . Melphalan and other DNA cross-linkers increase mitochondrial ROS in HeLa and HCT cells [57] and oxidative stress has been shown to increase melphalan cytotoxicity in chronic myeloid leukemia cells [58] . Thus, DCA could potentiate the effects of melphalan (as well as other cytostatic drugs) by inducing cellular oxidative stress, possibly because the mitochondrial metabolism is down-regulated to counterbalance the oxidative stress induced by continuous drug exposure.
In addition to mediating increased mitochondrial ROS, DCA also depletes substrate from the NAD + -generating LDHA step. This slows glycolytic ATP production, rendering the melphalan-resistant cells more sensitive to treatment. The increased reliance of NAD + -dependent aerobic glycolysis of the melphalan-resistant cells is also supported by the selective effect of the electron transport chain inhibitors metformin and antimycin A, which target the NAD + -generating steps. Metformin is well tolerated and widely used in the treatment of diabetes, and it has been shown to suppress breast and pancreatic tumor development and reprogram ovarian and breast cancer cells to a non-cancerous state [59] [60] [61] [62] [63] ; however, the molecular mechanisms by which metformin displays an anti-cancer effect and is selectively cytotoxic to melphalan-resistant myeloma cells require further study. Both IL-8 and VEGF are important mediators of hypoxia and oxidative stress signaling that stimulate proliferation and survival of MM cells [64] . In addition, IL-8 is a potent pro-inflammatory cytokine. Downstream signaling involves complex kinase networks including MAPKs, PI3Ks and PKC [36] . The two PI3K inhibitors LY294002 and wortmannin were selectively cytotoxic to the melphalan-resistant cells. LY294002 broadly targets PI3Ks and has been shown to inhibit CK2, mTOR and GSK3B [65] , while wortmannin targets PI3K-C2β and weakly inhibits mTOR and DNA-PK [66, 67] . The highly specific mTOR-inhibitor rapamycin was also selectively cytotoxic to the resistant cells. Rapamycin inhibits mTORC1 and may also inhibit mTORC2 in some cell types [68] . In the melphalan-resistant cells, mTOR signaling is apparently not AKT dependent, since AKT1-and pAKT1-levels were both reduced. Moreover, PTEN, which negatively regulates AKT, was more than twofold up-regulated at the mRNA level in the resistant cells. AKT1-independent activation of mTOR has been reported in several cell types, including B-lymphocyte cell lines [69] and follicular lymphoma cells [70] . In the tumor syndrome tuberous sclerosis (TSC) mTOR is indirectly activated by MAPK-mediated phosphorylation of TSC1 and 2 that alleviates inhibition of mTOR [71] . Notably we find that both TSC1 and 2 are significantly down-regulated at the mRNA level in the resistant cells (S2 Table) , potentially contributing to increased functional mTOR. Recent studies have assigned a central role of mTOR2C in the control of metabolic reprogramming in cancer cells. This function is AKT-independent and rather involves up-regulation of c-MYC [72, 73] , which was found to be 1.8-fold up-regulated at the mRNA level in the resistant cells. In addition, the glucocorticoid-stimulated kinase SGK1, which is a downstream target of mTORC2 and an important mediator of AKT-independent mTOR signaling [74] was fourfold up-regulated at the mRNA level in the melphalan-resistant cells (S2 Table) .
The p38MAPK inhibitors SB203580 and BIRB796 were both differently cytotoxic to the cell lines. These inhibitors also exhibit different specificities, with SB230580 inhibiting p38α and β, as well as CK1, GSK3, RIP2 and GAK, while BIRB796 inhibits p38α, β, γ and δ as well as JNK2. The overlapping specificities of the inhibitors as well as the inherent complexity and crosstalk between the various signaling pathways renders elucidation of the exact mechanisms involved to be extremely challenging; however, the selective cytotoxicity of BIRB796 towards the melphalan-resistant cells warrant further investigation into the involvement of JNK2 in melphalan resistance. JNK2 has a central role in stress signaling, including oxidative stress, and also mediates secretion of pro-inflammatory IL-8, thus potentially forming an autocrine stimulatory loop in the melphalan-resistant cells.
The involvement of AKR1C enzymes in melphalan resistance was substantiated by inhibitor studies as well as the ability of mehyl glyoxal-induced AKR1C3 to induce melphalan-resistance in the parental RPMI8226 cells. The AKR1C subfamily plays essential roles in the metabolism of steroid hormones and bile acids, and is involved in the pre-receptor regulation of nuclear and membrane-bound receptors [75] . Dysregulated AKR1C2 and C3 expression has been linked to the development of prostate, breast and endometrial carcinomas as well as leukemias, likely due to their ability to modify steroid hormones and prostaglandins (PDGs) [75] . Moreover, AKR1C3 has been identified as a potential therapeutic target in leukemia because its PGD2 reductase activity may prevent cell differentiation [76] . This activity also prevents formation of the pro-apoptotic 15-deoxy-PGJ2 [77] . In a recent drug screen to identify specific AKR1C3 inhibitors, tetracycline was initially identified as a potential AKR1C3-selective inhibitor. However subsequent analysis by mass spectrometry and NMR revealed that the active inhibitor was a breakdown product of tetracycline, (4-methyl(de-dimethylamine)-tetracycline (4-MDDT). Treatment of leukemia cells with 4-MDDT did not recapitulate the anti-leukemic property of pan-AKR1C inhibitors, suggesting that multiple AKR1C inhibition is likely required to elicit an anticancer effect in leukemia [78] , in agreement with our findings. In addition to endogenous substrates, AKR1C enzymes have been implicated in the metabolism of several exogenous substrates, including drugs, carcinogens and reactive aldehydes such as 4-hydroxynonenal (4HNE) [49] . AKR1C1-3 has been shown to possess a high specific activity for 4HNE reduction [51] , one of the most cytotoxic products of lipid peroxidation that is likely formed by melphalan-induced cellular peroxide [79] and increased plasma lipid peroxidation. A potential role of AKR1C1-3 in melphalan resistance could thus be a result of 4HNE processing. Although currently speculative, the AKR1C enzymes might also have a more subtle role in regulating the redox balance of cells under oxidative stress. They act primarily as reductases in vivo, (K d for NADPH in the nanomolar range) and could potentially contribute to influence the NADPH/NADP + balance. Since NADPH potently inhibits NAD + -dependent oxidation reactions at low μM concentrations, such regulation could ensure sufficient NAD + to allow active glycolytic ATP-generation in the melphalan-resistant cells.
Conclusions
Our results reveal the presence of several previously unrecognized mechanisms for acquired drug resistance against melphalan. The SILAC profiling approach identified a switch in metabolism towards aerobic glycolysis as well as modulated oxidative stress signaling in the resistant cells. The metabolic switch was not evident from the mRNA results alone and underscores the power of quantitative proteomic profiling to identify alterations in biological pathways under significant translational control, such as metabolic pathways during chronic stress [80] . The present in-depth analysis of a melphalan-sensitive cell line and its resistant derivative highlights several promising targets within metabolic and oxidative stress response pathways that should be further explored to overcome melphalan resistance in MM. Such studies are now in progress in our laboratory.
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